Guangshengtang announced that on April 24, 2025, the holding subsidiary Guangsheng Zhonglin received the “Drug Clinical Trial Approval Notice” issued by the State Drug Administration and agreed to clinical trials of GST-HG131 combined with GST-HG141 for the treatment of chronic hepatitis B. The aforementioned joint program was included in the “Pilot Project for Optimizing Clinical Trial Evaluation and Approval of Innovative Drugs” in March of this year, and this clinical trial application was efficiently approved, reflecting the country's great importance and policy support for major innovative drug research and development. The company will actively promote the triple oral treatment plan for hepatitis B and challenge clinical treatment of hepatitis B for patients treated with nucleoside analogs.

Guangshengtang announced that on April 24, 2025, the holding subsidiary Guangsheng Zhonglin received the “Drug Clinical Trial Approval Notice” issued by the State Drug Administration and agreed to clinical trials of GST-HG131 combined with GST-HG141 for the treatment of chronic hepatitis B. The aforementioned joint program was included in the “Pilot Project for Optimizing Clinical Trial Evaluation and Approval of Innovative Drugs” in March of this year, and this clinical trial application was efficiently approved, reflecting the country's great importance and policy support for major innovative drug research and development. The company will actively promote the triple oral treatment plan for hepatitis B and challenge clinical treatment of hepatitis B for patients treated with nucleoside analogs.